21 September 2021

Biochemical recurrence occurs in >20% of treated prostate cancer patients, mainly due to metastatic disease (>80%). In the multicenter clinical study ADOPT, 280 men with oligo-recurrent prostate cancer from 10 participating hospitals in the Netherlands are randomized to receive standard metastasis-targeted radiotherapy or metastasis-targeted radiotherapy in combination with 6 months of ADT. Biomaterial from eligible ADOPT patients will be used to establish the ADOPT biobank. Patients eligible for the ADOPT study will be asked to consent to blood collection prior to treatment and during 6 and 12 month follow-up. The ADOPT biobank plans to use new technology to identify and validate circulating tumor DNA (ctDNA) and extracellular vesicle (EV) biomarker. These will then be used as predictive and prognostic tools to improve the timing of clinical treatment and to more accurately monitor treatment response.

  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items


Dutch-Nordic Alliance for Precision Cancer Medicine launched

26 November 2021

The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.

read more

New Automated PBMC isolation method introduced in LMI.

21 September 2021

The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.

read more

Health-RI, geared up to accelerate

21 September 2021

The Dutch cabinet has selected Health-RI's National Growth Fund proposal for a national health data infrastructure. On 5 October, the kick-off will take place during a live meeting in Jaarbeurs Media Plaza in Utrecht.

read more

SUNRISE-CRC sub-biobank

21 September 2021

The main purpose of SUNRISE-CRC is to determine whether treatment with a high dose of sunitinib provides a better chance of survival and slows the progression of (colo)rectal cancer (CRC) more than standard treatment with TAS-102.

read more

PRECISE sub-biobank

21 September 2021

The aim of the PRECISE biobank is to develop the first, smart multi-modal liquid biopsy test service for the prediction of immune checkpoint inhibitor response in urothelial cancer (UC) patients – the PRECISE IVD.

read more

Lysine Metabolism sub-biobank

21 September 2021

Hereditary metabolic disorders form a large group of more than 1,400 rare disorders in which an error in the DNA causes abnormalities in the process in which proteins, fats and carbohydrates are converted into smaller building materials and energy.

read more